Avoro Capital Advisors’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.16B | Sell |
5,062,500
-48,611
| -1% | -$10.9M | 11.39% | 2 |
|
|
2025
Q4 | $1.09B | Buy |
5,111,111
+1,111
| +0% | +$229K | 10.71% | 2 |
|
|
2025
Q3 | $1.02B | Buy |
5,110,000
+130,000
| +3% | +$24.2M | 13.13% | 1 |
|
|
2025
Q2 | $860M | Sell |
4,980,000
-238,000
| -5% | -$38.8M | 15.05% | 1 |
|
|
2025
Q1 | $813M | Buy |
5,218,000
+114,945
| +2% | +$16.4M | 12.69% | 2 |
|
|
2024
Q4 | $703M | Buy |
5,103,055
+114,167
| +2% | +$15M | 9.94% | 3 |
|
|
2024
Q3 | $745M | Buy |
4,988,888
+792,227
| +19% | +$107M | 10.86% | 2 |
|
|
2024
Q2 | $572M | Buy |
4,196,661
+229,995
| +6% | +$31.3M | 7.62% | 3 |
|
|
2024
Q1 | $600M | Buy |
3,966,666
+211,111
| +6% | +$30.1M | 6.99% | 3 |
|
|
2023
Q4 | $473M | Buy |
3,755,555
+85,555
| +2% | +$8.53M | 6.53% | 3 |
|
|
2023
Q3 | $344M | Buy |
3,670,000
+89,445
| +2% | +$8.37M | 5.36% | 7 |
|
|
2023
Q2 | $320M | Buy |
3,580,555
+255,555
| +8% | +$22.2M | 4.34% | 10 |
|
|
2023
Q1 | $357M | Buy |
3,325,000
+225,000
| +7% | +$25.7M | 5.29% | 9 |
|
|
2022
Q4 | $379M | Buy |
3,100,000
+250,000
| +9% | +$29M | 5.66% | 7 |
|
|
2022
Q3 | $294M | Buy |
2,850,000
+575,000
| +25% | +$54.5M | 5.44% | 8 |
|
|
2022
Q2 | $211M | Buy |
2,275,000
+75,000
| +3% | +$7.07M | 4.18% | 10 |
|
|
2022
Q1 | $258M | Buy |
2,200,000
+200,000
| +10% | +$23.2M | 4.71% | 7 |
|
|
2021
Q4 | $269M | Buy |
2,000,000
+20,000
| +1% | +$2.97M | 4.58% | 7 |
|
|
2021
Q3 | $316M | Buy |
1,980,000
+80,000
| +4% | +$10.9M | 4.96% | 5 |
|
|
2021
Q2 | $250M | Buy |
+1,900,000
| New | +$253M | 4.35% | 7 |
|
|
2021
Q1 | – | Sell |
-1,800,000
| Closed | -$300M | – | 47 |
|
|
2020
Q4 | $300M | Hold |
1,800,000
| – | – | 5.17% | 6 |
|
|
2020
Q3 | $278M | Buy |
1,800,000
+50,000
| +3% | +$7.19M | 3.95% | 5 |
|
|
2020
Q2 | $259M | Sell |
1,750,000
-37,000
| -2% | -$5.08M | 5.12% | 6 |
|
|
2020
Q1 | $201M | Sell |
1,787,000
-78,000
| -4% | -$10.1M | 6.79% | 4 |
|
|
2019
Q4 | $259M | Sell |
1,865,000
-105,000
| -5% | -$11.7M | 7.62% | 3 |
|
|
2019
Q3 | $190M | Hold |
1,970,000
| – | – | 7.92% | 4 |
|
|
2019
Q2 | $227M | Buy |
1,970,000
+175,000
| +10% | +$20.9M | 7.84% | 4 |
|
|
2019
Q1 | $211M | Sell |
1,795,000
-185,000
| -9% | -$16.2M | 9.14% | 3 |
|
|
2018
Q4 | $124M | Buy |
1,980,000
+16,664
| +0.8% | +$1.05M | 7.42% | 4 |
|
|
2018
Q3 | $139M | Sell |
1,963,336
-100,000
| -5% | -$6.88M | 6.39% | 4 |
|
|
2018
Q2 | $137M | Hold |
2,063,336
| – | – | 5.28% | 5 |
|
|
2018
Q1 | $135M | Buy |
2,063,336
+382,312
| +23% | +$21.5M | 6.44% | 6 |
|
|
2017
Q4 | $67.3M | Buy |
1,681,024
+44,900
| +3% | +$1.63M | 4.36% | 8 |
|
|
2017
Q3 | $59.3M | Buy |
1,636,124
+645,200
| +65% | +$18.5M | 4.6% | 7 |
|
|
2017
Q2 | $27.5M | Buy |
990,924
+290,000
| +41% | +$7.66M | 3.47% | 11 |
|
|
2017
Q1 | $19.6M | Buy |
700,924
+155,721
| +29% | +$3.94M | 2.51% | 14 |
|
|
2016
Q4 | $11M | Buy |
545,203
+500,000
| +1,106% | +$9.99M | 2.23% | 17 |
|
|
2016
Q3 | $909K | Buy |
+45,203
| New | +$746K | 0.16% | 39 |
|
Other funds holding ASND
RCM
PA
Avoro Capital Advisors's ASND Position: Q1 2026 in Review
Avoro Capital Advisors reduced its Ascendis Pharma A/S (ASND) stake by 0.95% in Q1 2026, selling an estimated $10.9M and leaving 5,062,500 shares worth $1.16B. The position accounts for 11.39% of the portfolio, ranked #2.
Avoro Capital Advisors first reported a position in ASND in Q3 2016 and has held it in 38 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.
- Avoro Capital Advisors held 5,062,500 shares of Ascendis Pharma A/S worth $1.16B as of Q1 2026.
- Avoro Capital Advisors sold 48,611 Ascendis Pharma A/S shares in Q1 2026, an estimated $10.9M.
- Ascendis Pharma A/S made up 11.39% of Avoro Capital Advisors's portfolio in Q1 2026, its #2 holding.
- Avoro Capital Advisors first reported a position in Ascendis Pharma A/S in Q3 2016 and has held it in 38 quarters since.
- 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.
Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.